Cargando…

Extracellular NM23 Protein as a Therapeutic Target for Hematologic Malignancies

An elevated serum level of NM23-H1 protein is a poor prognostic factor in patients with various hematologic malignancies. The extracellular NM23-H1 protein promotes the in vitro growth and survival of acute myelogenous leukemia (AML) cells and inversely inhibits the in vitro survival of normal perip...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okabe-Kado, Junko, Kasukabe, Takashi, Kaneko, Yasuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3175692/ https://www.ncbi.nlm.nih.gov/pubmed/21941554 http://dx.doi.org/10.1155/2012/879368

Ejemplares similares

Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts
por: Kasukabe, Takashi, et al.
Publicado: (2005)

Inhibition of abl Oncogene Tyrosine Kinase Induces Erythroid Differentiation of Human Myelogenous Leukemia K562 Cells
por: Honma, Yoshio, et al.
Publicado: (1990)

Combined analysis of differentiation inhibitory factor nm23-H1 and nm23-H2 as prognostic factors in acute myeloid leukaemia.
por: Wakimoto, N., et al.
Publicado: (1998)

Protein Arginine Methyltransferases as Therapeutic Targets in Hematological Malignancies
por: Sauter, Camille, et al.
Publicado: (2022)

Extracellular Vesicles in Hematological Malignancies: From Biomarkers to Therapeutic Tools
por: Khalife, Jihane, et al.
Publicado: (2020)

Extracellular NM23 Signaling in Breast Cancer: Incommodus Verum
por: Buxton, Iain L.O., et al.
Publicado: (2011)

BCL-2 as therapeutic target for hematological malignancies
por: Perini, Guilherme Fleury, et al.
Publicado: (2018)

Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies
por: Markouli, Mariam, et al.
Publicado: (2022)

Role of Extracellular Vesicles in Hematological Malignancies
por: Raimondo, Stefania, et al.
Publicado: (2015)

Therapeutic Targeting of Notch Signaling Pathway in Hematological Malignancies
por: Sorrentino, Claudia, et al.
Publicado: (2019)

Expression of nm23‐Hl and nm23‐H2 Proteins in Prostate Carcinoma
por: Konishi, Noboru, et al.
Publicado: (1993)

Super-enhancers: critical roles and therapeutic targets in hematologic malignancies
por: Jia, Yunlu, et al.
Publicado: (2019)

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
por: He, Yonghan, et al.
Publicado: (2020)

CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
por: Testa, Ugo, et al.
Publicado: (2019)

Expression of nm23-H1 and nm23-H2 protein in endometrial carcinoma.
por: Watanabe, J., et al.
Publicado: (1995)

Extracellular Vesicles in Hematological Malignancies: From Biology to Therapy
por: Caivano, Antonella, et al.
Publicado: (2017)

Therapeutic Benefits of Selenium in Hematological Malignancies
por: Ehudin, Melanie A., et al.
Publicado: (2022)

Therapeutic Advances in Immunotherapies for Hematological Malignancies
por: Nogami, Ayako, et al.
Publicado: (2022)

Contribution of extracellular vesicles in normal hematopoiesis and hematological malignancies
por: Ghafouri-Fard, Soudeh, et al.
Publicado: (2021)

HMGA Proteins in Hematological Malignancies
por: Minervini, Angela, et al.
Publicado: (2020)

CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies
por: Testa, Ugo, et al.
Publicado: (2014)

Macrophage-Based Therapeutic Strategies in Hematologic Malignancies
por: Khalili, Saeed, et al.
Publicado: (2023)

NME/NM23/NDPK and Histidine Phosphorylation
por: Adam, Kevin, et al.
Publicado: (2020)

Targeting immune checkpoints in hematological malignancies
por: Salik, Basit, et al.
Publicado: (2020)

Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological Malignancies
por: Wolska-Washer, Anna, et al.
Publicado: (2022)

Gab Adapter Proteins as Therapeutic Targets for Hematologic Disease
por: Verma, Sheetal, et al.
Publicado: (2012)

CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies
por: Bruno, Samantha, et al.
Publicado: (2022)

Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies
por: Wang, Shifen, et al.
Publicado: (2023)

Targeting DNA Repair Pathways in Hematological Malignancies
por: Alhmoud, Jehad F., et al.
Publicado: (2020)

Targeting the integrated stress response in hematologic malignancies
por: Nwosu, Gus O., et al.
Publicado: (2022)

Myeloid-Derived Suppressor Cells as Therapeutic Target in Hematological Malignancies
por: De Veirman, Kim, et al.
Publicado: (2014)

Tetraspanins as therapeutic targets in hematological malignancy: a concise review
por: Beckwith, Kyle A., et al.
Publicado: (2015)

The Role of Extracellular Vesicles in the Pathogenesis of Hematological Malignancies: Interaction with Tumor Microenvironment; a Potential Biomarker and Targeted Therapy
por: Das, Kaushik, et al.
Publicado: (2023)

AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma
por: Yan, Siyang, et al.
Publicado: (2019)

High-throughput analysis and functional interpretation of extracellular vesicle content in hematological malignancies
por: Tanasi, Ilaria, et al.
Publicado: (2020)

RHOA Therapeutic Targeting in Hematological Cancers
por: Santos, Juliana Carvalho, et al.
Publicado: (2023)

Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and K-ras mutation in ovarian carcinoma: correlation with tumour progression and nm23 gene expression.
por: Mandai, M., et al.
Publicado: (1995)

The potential for targeting extracellular LOX proteins in human malignancy
por: Mayorca-Guiliani, Alejandro, et al.
Publicado: (2013)

Notch signaling: its roles and therapeutic potential in hematological malignancies
por: Gu, Yisu, et al.
Publicado: (2016)

Exosome-Mediated Therapeutic Strategies for Management of Solid and Hematological Malignancies
por: Allegra, Alessandro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qg3m0s4vtfv27d161lt3n24s54